Submitted by Anonymous (not verified) on 12 September 2023 - 13:59
Human medicines European public assessment report (EPAR): Pemazyre, pemigatinib, Cholangiocarcinoma, Date of authorisation: 26/03/2021, Revision: 6, Status: Authorised
Source: